Ontario Teachers Pension Plan Board Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ontario Teachers Pension Plan Board acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,482 shares of the company's stock, valued at approximately $749,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. International Assets Investment Management LLC boosted its position in IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Clearbridge Investments LLC boosted its position in IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock worth $171,891,000 after purchasing an additional 308,493 shares in the last quarter. Vontobel Holding Ltd. boosted its position in IDEXX Laboratories by 3,325.0% during the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock worth $111,229,000 after purchasing an additional 213,731 shares in the last quarter. American Century Companies Inc. boosted its position in IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock worth $274,179,000 after purchasing an additional 177,226 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its position in IDEXX Laboratories by 4,193.1% during the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company's stock worth $62,601,000 after purchasing an additional 125,498 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX traded down $1.31 during trading hours on Friday, hitting $417.24. 503,439 shares of the company were exchanged, compared to its average volume of 503,414. The company has a market capitalization of $34.17 billion, a PE ratio of 40.44, a PEG ratio of 3.63 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The firm has a fifty day simple moving average of $462.53 and a 200-day simple moving average of $481.11. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company posted $2.53 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the topic of several recent research reports. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research report on Thursday, October 10th. BTIG Research assumed coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They set a "buy" rating and a $580.00 price target for the company. Piper Sandler restated a "neutral" rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Finally, Barclays dropped their price target on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.